



The Trendlines Group Reports Record 2018 Third Quarter Profit Portfolio Value Exceeds US\$102 Million (SGD141 Million)

Misgav, Israel and Singapore, 8 November 2018 – The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries, “**Trendlines**” or the “**Group**”), a leading Israeli-based investment and innovation commercialization company focused on early-stage, high growth medical and agricultural technologies, announced its financial results for the third quarter ended 30 September 2018 (“**Q3 2018**”).

Third Quarter 2018 Highlights

Group Financials

- **Fair Value of Portfolio:** US\$102.5 million as at 30.09.2018 (31.12.2017: US\$96.8 million)
- **Total Income:** US\$6.6 million (Q3 2017: US\$6.8 million)
- **Total Expenses:** US\$2.3 million (Q3 2017: US\$2.7 million)
- **Net Income:** US\$3.1 million (Q3 2017: US\$3.0 million)
- **Total Current Assets:** US\$13.9 million as at 30.09.18 (31.12.17: US\$20.4 million)
- **Book Value:** US\$92.8 million as at 30.09.18 (31.12.17: US\$92.9 million)

Corporate/Business Developments

- ApiFix Ltd. performed over 250 surgeries.
- Leviticus Cardio Ltd. successfully completed third chronic animal study.
- The SIAS 19th INVESTORS' CHOICE AWARDS named Trendlines “Winner of Singapore Corporate Governance Award, Most Improved” for a company trading on the SGX.
- New medical portfolio company, Hyblate Medical Ltd., established in Israel.
- Trendlines’ cost-reduction program is on track with Q3 2018 expenses being 14% lower than Q3 2017.
- Total number of portfolio companies are 51 of which 17 are in commercialization.

Post Q3 2018 Developments

- FruitSpec Ltd. announced the completion of successful field studies and received a patent in the United States for its fruit yield estimate technology.
- liberDi Ltd. completed successful pre-clinical trials for their portable, home dialysis system.
- Escala Medical Ltd. launched a fund-raising campaign on Exit Valley Ltd.

- Saturas Ltd. completed successful field trials in California (May-October 2018) and presented the company's technology to China's Vice President Wang Qishan at the Israel Innovation Summit October 2018.

Q3 2018 Financial Results

Chairman and CEO Steve Rhodes commented on Trendlines' third quarter financial results, "For the first time, the value of Trendlines' portfolio has crossed the US\$100 million mark and stands at US\$102.5 million (~SGD141 million). Additionally, Q3 2018 was our most profitable quarter since the Company's listing in November 2015. Trendlines continues to successfully execute on its value-building business plan.

Total net portfolio value was up US\$6.3 million compared to 30 June 2018. The increase in portfolio value for the quarter was mainly due to the completion of fund-raising exercises at better terms as well as commercial and technological progress of portfolio companies."

Total income in Q3 2018 was US\$6.6 million (similar to Q3 2017). Total expenses decreased by approximately US\$0.4 million in Q3 2018 as compared to Q3 2017; Net income in Q3 2018 was US\$3.1 million, compared to US\$3 million in Q3 2017. So far, Trendlines has met its goals as set out in the cost reduction plan announced in October 2017."

Commenting on portfolio and business developments during the third quarter, Chairman and CEO Todd Dollinger said, "It is encouraging to observe the important developments of a number of our portfolio companies. ApiFix Ltd. completed over 250 surgeries and Gordian Surgical Ltd. surpassed the 500 count for surgeries with their integrated port closure system. The Stimatix GI Ltd. product launch remains on schedule for worldwide rollout.

Our '[10 Companies to Watch](#)' report, published quarterly, continues to update our investors on the most significant developments and milestones that these select companies reach. This quarter, we updated the report to include a number of new companies not previously included."

We were honored to receive the SIAS Corporate Governance Award for 'Most Improved Company' trading on the SGX. This award confirms our commitment to providing our investors with timely and transparent information on our company."

For full financial information, please see our announcement to the SGX: Unaudited Financial Statements for the three months ended 30 September 2018.

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore

Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

Investor Contact Information

Israel
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

This press release has been prepared by The Trendlines Group Ltd. (the “Company”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”) for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)